Clinical Trial

GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5

Study acronym: HD10/DSMMXX
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab-, Talquetamab-, and JNJ-79635322-based Combination Regimens in Participants with Newly Diagnosed Transplant Eligible Multiple Myeloma OBJECTIVES: To evaluate the safety and tolerability of teclistamab-, talquetamab-, and JNJ-79635322-based combination regimens over the entire treatment phase for each arm, in participants with ND-TEMM To evaluate the efficacy of teclistamab- and talquetamab-based combination regimens as induction and post-transplant maintenance treatments; JNJ-79635322-based combinations as induction and as replacement for HDT+ASCT following induction; and teclistamab in combination with talquetamab
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-01-19; most recent amendment 2025-12-17.
Trial Details
NCT Number NCT05695508
Lead Sponsor University of Heidelberg Medical Center
Collaborators: Janssen Research & Development, LLC, Deutsche Studiengruppe Multiples Myelom (DSMM)
Conditions Multiple Myeloma
Enrollment 160 participants
Start Date 2022-12-01
Primary Completion 2028-09-15 (estimated)
Study Completion 2029-09-15 (estimated)
Updated on ClinicalTrials.gov 2025-12-24